AN EVALUATION OF THE ASSOCIATION OF CDKN2B (P15) DNA METHYLATION WITH RESPONSE AND SURVIVAL IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) TREATED IN THE AZA-001 TRIAL

被引：0

作者：

Herman, J. ^{[1
]}

Mufti, G. ^{[2
]}

MacBeth, K. ^{[3
]}

Seymour, J. ^{[4
]}

Fenaux, P. ^{[5
]}

Gore, S. ^{[1
]}

Santini, V. ^{[6
]}

Lucy, L. ^{[3
]}

Beach, C. ^{[3
]}

机构：

[1] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[2] Kings Coll London, London WC2R 2LS, England

[3] Celgene Corp, San Francisco, CA USA

[4] Peter MacCallum Canc Inst, Melbourne, Australia

[5] Hop Avicenne, Serv hematol clin, F-93009 Bobigny, France

[6] Univ Careggi, Azienda Osped, Florence, Italy

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0309

引用

页码：124 / 124

页数：1

共 8 条

[1] Relationship among gene methylation, azacitidine treatment, and survival in patients with higher-risk myelodysplastic syndromes (MDS): results from the AZA-001 trial
Herman, James G.
Gore, Steven
Mufti, Ghulam
Fenaux, Pierre
Santini, Valeria
Silverman, Lewis
Seymour, John
Griffiths, Elizabeth
Caraway, Hetty
MacBeth, Kyle
McKenzie, David
Backstrom, Jay
Beach, C. L.
CANCER RESEARCH, 2009, 69
[2] A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial
Gore, Steven D.
Fenaux, Pierre
Santini, Valeria
Bennett, John M.
Silverman, Lewis R.
Seymour, John F.
Hellstrom-Lindberg, Eva
Swern, Arlene S.
Beach, Charles. L.
List, Alan. F.
HAEMATOLOGICA, 2013, 98 (07) : 1067 - 1072
[3] Re-Evaluation of the Efficacy of Azacitidine (AZA) In Patients From the AZA-001 Study with Higher-Risk Myelodysplastic Syndromes (MDS) Classified by WHO Criteria and WPSS Risk.
Gattermann, Norbert
Sanz, Guillermo F.
Giagounidis, Aristoteles
Seymour, John F.
Fenaux, Pierre
Santini, Valeria
Mufti, Ghulam J.
Muus, Petra
Ramos, Fernando
Lucy, Lela M.
Beach, C. L.
Silverman, Lewis R.
BLOOD, 2010, 116 (21) : 1643 - 1644
[4] Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study
Seymour, John F.
Bennett, John M.
List, Alan F.
Mufti, Ghulam J.
Gore, Steven D.
Fenaux, Pierre
Santini, Valeria
Hetzer, Joel
Songer, Stephen
Skikne, Barry S.
Beach, C. L.
BLOOD, 2012, 120 (21)
[5] Overexpression of CDKN2B (p15INK4B) and altered global DNA methylation status in mesenchymal stem cells of high-risk myelodysplastic syndromes
A Poloni
G Maurizi
D Mattiucci
S Amatori
B Fogliardi
B Costantini
M Mariani
S Mancini
A Olivieri
M Fanelli
P Leoni
Leukemia, 2014, 28 : 2241 - 2244
[6] Overexpression of CDKN2B (p15INK4B) and altered global DNA methylation status in mesenchymal stem cells of high-risk myelodysplastic syndromes
Poloni, A.
Maurizi, G.
Mattiucci, D.
Amatori, S.
Fogliardi, B.
Costantini, B.
Mariani, M.
Mancini, S.
Olivieri, A.
Fanelli, M.
Leoni, P.
LEUKEMIA, 2014, 28 (11) : 2241 - 2244
[7] Evaluation of International Working Group 2006 Response Criteria in Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agent Monotherapy in the Frontline Setting
Bewersdorf, Jan Philipp
Wei, Wei
Jaiani, Anna
Patel, Prital
Mehta, Rajni
Neparidze, Natalia
Shallis, Rory M.
Podoltsev, Nikolai
Brunner, Andrew M.
Zeidan, Amer M.
BLOOD, 2021, 138 : 3701 - +
[8] EFFECT OF AZACITIDINE (AZA) vs LOW-DOSE ARA-C (LDAC) ON OVERALL SURVIVAL (OS), HEMATOLOGIC RESPONSE, TRANSFUSION INDEPENDENCE, AND SAFETY IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)
Fenaux, P.
Gattermann, N.
Seymour, J.
Hellstrom-Lindberg, E.
Mufti, G. J.
Duehrsen, U.
Gore, S.
Ramos, F.
Beyne-Rauzy, O.
Dombret, H.
List, A.
McKenzie, D.
Backstrom, J.
Allen, A.
Beach, C. L.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 90 - 90

← 1 →